Kura Oncology to Report Third Quarter 2024 Financial Results
Kura Oncology (Nasdaq: KURA) announced it will release its third quarter 2024 financial results after U.S. market close on Thursday, November 7, 2024. The company will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT on the same day, featuring management's discussion of financial results and a corporate update. Investors can access the call via phone or watch the webcast through the company's website.
Kura Oncology (Nasdaq: KURA) ha annunciato che pubblicherà i suoi risultati finanziari del terzo trimestre 2024 dopo la chiusura del mercato statunitense giovedì 7 novembre 2024. L'azienda ospiterà un webcast e una chiamata conferenza alle 16:30 ET / 13:30 PT dello stesso giorno, con la discussione dei risultati finanziari e un aggiornamento aziendale da parte della direzione. Gli investitori possono accedere alla chiamata tramite telefono o guardare il webcast attraverso il sito web dell'azienda.
Kura Oncology (Nasdaq: KURA) anunció que publicará sus resultados financieros del tercer trimestre de 2024 después del cierre del mercado estadounidense el jueves 7 de noviembre de 2024. La compañía organizará una transmisión en línea y una llamada de conferencia a las 4:30 p.m. ET / 1:30 p.m. PT el mismo día, en la que se discutirá los resultados financieros y se ofrecerá una actualización corporativa. Los inversores pueden acceder a la llamada por teléfono o ver la transmisión a través del sitio web de la empresa.
Kura Oncology (Nasdaq: KURA)는 2024년 11월 7일 목요일 미국 시장 종료 후 2024년 3분기 재무 결과를 발표할 것이라고 발표했습니다. 이날 오후 4시 30분 ET / 오후 1시 30분 PT에 경영진이 재무 결과에 대해 논의하고 회사 업데이트를 제공하는 웹캐스트 및 컨퍼런스 콜을 개최할 예정입니다. 투자자는 전화를 통해 콜에 접속하거나 회사 웹사이트를 통해 웹캐스트를 시청할 수 있습니다.
Kura Oncology (Nasdaq: KURA) a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 après la clôture du marché américain le jeudi 7 novembre 2024. L'entreprise tiendra un webinaire et une conférence téléphonique à 16h30 ET / 13h30 PT le même jour, au cours desquels la direction discutera des résultats financiers et fournira une mise à jour de l'entreprise. Les investisseurs peuvent accéder à l'appel par téléphone ou regarder le webinaire via le site Web de l'entreprise.
Kura Oncology (Nasdaq: KURA) gab bekannt, dass das Unternehmen seine Finanzergebnisse für das dritte Quartal 2024 nach Marktschluss in den USA am Donnerstag, den 7. November 2024, veröffentlichen wird. Am selben Tag wird um 16:30 Uhr ET / 13:30 Uhr PT eine Webkonferenz und Telefonkonferenz stattfinden, bei der das Management die Finanzergebnisse und ein Unternehmensupdate bespricht. Investoren können die Konferenz telefonisch erreichen oder das Webcast über die Website des Unternehmens ansehen.
- None.
- None.
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2024 financial results after the close of U.S. financial markets on Thursday, November 7, 2024. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing (800) 225-9448 for domestic callers and (203) 518-9708 for international callers and entering the conference ID: KURAQ3. A live webcast and archived replay of the event will be available here or online from the investor relations section of the company website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. Kura is evaluating KO-2806, a next-generation farnesyl transferase inhibitor (FTI), in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.
Contacts
Investors:
Pete De Spain
Executive Vice President, Investor Relations &
Corporate Communications
(858) 500-8833
pete@kuraoncology.com
Media:
Cassidy McClain
Vice President
Inizio Evoke Comms
(619) 849-6009
cassidy.mcclain@inizioevoke.com
FAQ
When will Kura Oncology (KURA) release Q3 2024 earnings?
What time is Kura Oncology's (KURA) Q3 2024 earnings call?
How can investors access Kura Oncology's (KURA) Q3 2024 earnings call?
